Get started
Author

Quentin Kimana

Observed names: Kimana Quentin, Q. Kimana
ORCID: 0009-0006-8831-7775
Observed ORCID: 0009-0006-8831-7775
OpenAlex ID: A5137167307
Clinicogenomic Characterization of Primary Sclerosing Cholangitis–Associated Biliary Tract Cancers
2025 · Xin Wang, Jaime Ivan Haro-Silerio, et al. · Clinical Cancer Research · 4
ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response
2026 · Supriya Peshin, Fen Saj, et al. · JCO Precision Oncology · 1
Association of angiogenic, fibrotic, and immunosuppressive tumor microenvironment with immunotherapy outcomes in metabolic disease–associated biliary tract cancers.
2026 · Quentin Kimana, Iwan Paolucci, et al. · Journal of Clinical Oncology · 1
Beyond fibroblast growth factor receptor 2 (FGFR2) fusions: Mutations and amplifications in intrahepatic cholangiocarcinoma.
2026 · Felicity David, Fen Saj, et al. · Journal of Clinical Oncology · 1
Association between obesity, molecular subtype, and immunotherapy outcomes in intrahepatic cholangiocarcinoma: The obesity paradox.
2026 · Fen Saj, Quentin Kimana, et al. · Journal of Clinical Oncology · 1
ERBB3 driver genomic alterations in intrahepatic cholangiocarcinoma: A genomic landscape and clinical outcome study.
2026 · Mridula Nadamuni, Quentin Kimana, et al. · Journal of Clinical Oncology · 1
Multimodal evaluation of metabolic dysfunction–associated steatotic liver disease (MASLD)–related biliary tract cancer (BTC) and immunotherapy outcomes.
2025 · Nakul Manish Shah, Quentin Kimana, et al. · Journal of Clinical Oncology · 1
Association of gut microbiota with therapy efficacy and prognosis in biliary tract cancer.
2025 · Fen Saj, Ashish Damania, et al. · Journal of Clinical Oncology · 1
PDF
Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
2026 · Nakul M. Shah, Beatriz Alvarado-Hernandez, et al. · Clinical Cancer Research
Correlation of immune remodeling linked to obesity with immunotherapy outcomes in cholangiocarcinoma: An externally validated international cohort study.
2026 · Antonella Cammarota, Fen Saj, et al. · Journal of Clinical Oncology
Real-world outcomes of microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) biliary tract cancers (BTC).
2026 · Madhulika Eluri, Andrés J. Muñoz Martín, et al. · Journal of Clinical Oncology
Comprehensive genomic profiling to identify molecular determinants of efficacy of IDH1 inhibition in intrahepatic cholangiocarcinoma.
2026 · Sunyoung S. Lee, Nikolas Naleid, et al. · Journal of Clinical Oncology
PDF
Abstract 3075: FGFR2b is a highly prevalent and actionable cell surface target in intrahepatic cholangiocarcinoma
2026 · Nakul M. Shah, Beatriz Alvarado-Hernandez, et al. · Cancer Research
Safety and efficacy of liver-directed radiotherapy after chemoimmunotherapy for advanced cholangiocarcinoma: an early report from a large tertiary cancer center
2025 · Abdulmoiz Asif, Abdulmoid Asif, et al. · Journal of Gastrointestinal Oncology
94P The association between tumor immunogenomic features and first-line (1L) therapeutic outcomes in advanced biliary tract cancer (BTC)
2025 · N. Shah, J. Symons, et al. · Annals of Oncology
342eP Multiomic characterization of early and metastatic biliary tract cancer (BTC)
2025 · N.M. Shah, J. Symons, et al. · Annals of Oncology
PDF
Works count: 16
Citation count: 11
H-index: 1
I10-index:
Year
Topic
Type